MTOR and prostate carcinoma: The mTOR inhibitor CCI779 showed anti-cancer activity in colorectal carcinoma and prostate cancer cases [28,29]; here, we also showed the anti-cervical cancer effects of CC1779 in vitro and in vivo (Figure 6).